Gastrointestinal bleeding and the prevention of thromboembolism by Marcinkonytė, Aušra et al.
116 www.journals.viamedica.pl/medical_research_journal
CASE REPORT
Aušra Marcinkonytė, Daiva Emilija Rekienė, Jonas Jucevičius, Laima Jankauskienė
Lithuanian University of Health Sciences, Kaunas, Lithuania
Gastrointestinal bleeding and the 
prevention of thromboembolism
ABSTRACT
About 2 percent of developed countries population use vitamin K antagonists (VKA), such as warfarin. 
These anticoagulation drugs are commonly prescribed for the purpose of thromboembolism prevention, 
in cases of atrial fibrillation, mechanical heart valves, deep vein thrombosis, pulmonary embolism and 
etc. The frequency of VKA prescription is massively increasing in the whole world. The main reason for 
it is the ageing of the population. As the usage of anticoagulants is increasing, doctors more often get 
to encounter patients with gastrointestinal bleeding taking anticoagulating drugs. The treatment of these 
patients is difficult because there are several important factors that have to be considered while choosing 
the tactic of treatment, such as the intensity of bleeding, coagulation, thrombotic risk and endoscopic 
findings. Even if practical guidelines partially indicate the main principles of actions for similar cases, the 
treatment of bleeding patients taking anticoagulants remains seriously challenging. This article contains 
clinical case report and the discussion of the treatment that has been chosen in this case, based on 
practical guidelines provided by American Society for Gastrointestinal Endoscopy (ASGE), European 
Society of Gastrointestinal Endoscopy (ESGE) and European Society of Cardiology (ESC). This topic is 
also addressed in guidelines from the American College of Gastroenterology, the American College of 
Chest Physicians, the American College of Cardiology, which give similar recommendations.
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Introduction
About 2 per cent of developed countries population 
use vitamin K antagonists (VKA), such as warfarin. 
These anticoagulation drugs are commonly prescribed 
for the purpose of thromboembolism prevention, in 
cases of atrial fibrillation, mechanical heart valves, deep 
vein thrombosis, pulmonary embolism and etc. The 
frequency of VKA prescription is massively increasing 
in the whole world. The main reason for it is the ageing 
of the population. As the usage of anticoagulants is 
increasing, doctors more often get to encounter patients 
with gastrointestinal bleeding taking anticoagulating 
drugs. The treatment of these patients is difficult be-
cause there are several important factors that have to be 
considered while choosing the tactic of treatment, such 
as the intensity of bleeding, coagulation, thrombotic risk 
and endoscopic findings. Even if practical guidelines 
partially indicate the main principles of actions for similar 
cases, the treatment of bleeding patients taking anti-
coagulants remains seriously challenging. This article 
contains clinical case report and the discussion of the 
treatment that has been chosen in this case, based 
on practical guidelines provided by American Society 
for Gastrointestinal Endoscopy (ASGE), European 
Society of Gastrointestinal Endoscopy (ESGE) and 
European Society of Cardiology (ESC). This topic is 
also addressed in guidelines from the American College 
of Gastroenterology, the American College of Chest 
Physicians, the American College of Cardiology, which 
give similar recommendations.
Case report
52 years old woman having the complaints of vomit-
ing with blood clots, black fieces and general weakness 
has been delivered to the emergency department. 
A day before hospitalization the patient got nausea 
after coughing, had vomited blood with clots. One day 
later vomiting occurred once again, black fieces showed 
up as well. The patient has been delivered to the emer-
gency department by ambulance and has been hospi-
talized for more detailed examination and treatment. 
The patient had rheumatism, mitral valve was re-
placed with a mechanical prosthesis in 2008. She also 
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had a myocardial infarction and coronary arteries bypass 
in 2008. Artificial cardiac pacemaker (ECS IKDVR) was 
implanted in 2011. The patient also has arterial hyper-
tension, permanent atrial fibrillation, type II diabetes. 
The patient permanently takes metformin, gliclazide, 
metoprolol, spironolactone, torasemide. She also often 
takes diclofenac to reduce the pain of her joints. To pre-
vent thromboembolic events which can occur because 
of mechanical mitral valve prosthesis and permanent 
atrial fibrillation, the patient takes warfarin.
During the physical examination, the patient was 
fully conscious, oriented and available for contact. The 
skin and visible mucous membranes have been pink, 
the tongue has been dry, covered with white plaque. 
Breathing rate has been 16 per minute. Breath sound in 
the lungs has been vesicular, without crackles on both 
sides. Heartbeat has been arrhythmic with the sound of 
a mechanical valve’s prosthesis. Arterial blood pressure 
110/80 mmHg, heart rate 150 times per minute. The 
abdomen has been soft, but sensitive in the whole area. 
The percussion of kidneys hasn’t been painful. There 
have been no oedemas in her legs.
Blood test results: red blood cells (RBC) 3,27 x 
1012/l, haemoglobin (Hb) 103 g/l. Coagulation tests: 
SPA 25 %, INR 2,19.
Endoscopy showed a bleeding gastric ulcer in the 
angular area, which has been around 0.7 cm in size and 
with a clot underneath. The bleeding has been stopped 
by clamping. The treatment has been continued with 
esomeprazole/pantoprazole 80 mg bolus intravenously, 
continuing 8 mg per hour by automatic syringe pump 
for 3 days.
A blood test was repeated after the endoscopy 
and it showed that the amount of haemoglobin was 
getting lower (100•88•81 g/l). The patient had a blood 
transfusion, 2 units of red blood cells mass were given.
Next morning the health state of the patient was 
improved, general weakness seemed to be reduced, 
there were no signs of bleeding.
The treatment has been continued with Sol. Esome-
prazole 40 mg twice a day intravenously for 2 days, 
later Caps. Omeprazole 20 mg twice a day orally 
were prescribed.
In case of gastrointestinal bleeding, the decision to 
stop taking warfarin and change it with low molecular 
weight heparin (LMWH) was made, so the patient has 
started getting Sol. Nadroparin 2850 IU twice a day sub-
cutaneously.
Tab. Tardyferon 80 mg once a day orally has been 
prescribed additionally to treat anaemia.
The patient was discharged from hospital after 
a week. On the day of discharge, her health was 
improved, there were no signs of recurrent bleeding. 
Heartbeat has been arrhythmic with the sound of a me-
chanical valve’s prosthesis. Arterial blood pressure 
90/64 mmHg, heart rate 64 times per minute. Breath 
sound in the lungs has been vesicular, without crackles 
on both sides. The abdomen has been soft, slightly 
sensitive in the epigastric area. 
It has been recommended to continue the treatment 
with Caps. Omeprazole 20 mg twice a day orally, Tab. 
Tardyferon 80 mg once a day orally, Sol. Nadroparin 
2850 IU twice a day subcutaneously. Also to avoid 
nonsteroidal anti-inflammatory drugs (NSAID), to use 
Caps. Tramadol if severe pain occurs. It has been 
planned to repeat endoscopy after a month and then 
decide if warfarin using should be restarted.
Endoscopy was repeated after a month, the healed 
ulcer was observed and nadroparin was changed with 
warfarin again. Warfarin resumption was started after 
more than a month since gastrointestinal bleeding 
occurred. There has been found Helicobacter pylori 
infection and it has been treated with antibiotics. It was 
also recommended to continue taking iron preparation 
to treat and prevent anaemia.
Discussion
The patient is 52 years old woman with the signs 
of gastrointestinal bleeding- vomiting with blood clots 
and melena. The patient also uses warfarin, because 
she has mechanical mitral valve prosthesis and perma-
nent atrial fibrillation, which are dangerous because of 
increased risk of thromboembolism. Anticoagulant war-
farin certainly contributes to avoiding thromboembolic 
events, yet significantly increases the risk of bleeding. 
Gastrointestinal bleeding that occurred for the patient 
might be the result of warfarin usage. Based on litera-
ture sources, in cases of active and heavy bleeding, the 
usage of anticoagulants should be discontinued, except 
minimal rectal bleeding. [1, 2] In case of this specific 
patient, bleeding has been active, with a decreasing 
amount of haemoglobin, consequently, warfarin has 
been discontinued, according to the recommendations 
of literature sources.
Early endoscopic intervention is the main measure 
to stop gastrointestinal bleeding, so this procedure 
should be organized immediately. [2] Anticoagulants 
users’ blood coagulation, which is mainly reflected by 
the international normalized ratio (INR), can be over the 
therapeutic value, that is why it is important to measure 
INR during the patient preparation for the endoscopic 
procedure and to take additional means for restoring 
normal coagulation. According to ASGE practical guide-
lines, in cases when bleeding is active, but INR value 
fits in therapeutic range (<  2.5), it is not recommended 
to postpone endoscopic procedure in the purpose of 
restoring coagulation. However, if INR is > 3, there 
is a need to take actions to normalize coagulation of 
blood. Vitamin K, prothrombin complex concentrate 
(PCC) or fresh frozen plasma (FFP) might be a choice in 
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this case. For all the patients, except those with minimal 
rectal bleeding and those with INR < 5, VKA should be 
discontinued and administered Vitamin K. A decision to 
give PCC (or FFP if there is no possibility to use PCC) 
should be taken depending on patient‘s bleeding in-
tensity, INR value, the timing of endoscopic procedure 
and individual risk for thrombosis. PCC should be given 
to intensively bleeding, critical state patients with per-
sistent or permanent haemodynamic instability, even in 
those cases when INR value fits the therapeutic range. 
INR should be measured every 20–30 minutes until 
the end of the PCC infusion. If INR remains > 1.5, one 
more dose of PCC should be given. After 6–8 hours INR 
should be measured again, and then once a day until 
the situation stays critical. It is recommended to admin-
ister Vitamin K together with PCC to avoid coagulopathy 
which can occur 12–24 hours after INR normalization 
when infused coagulation factors are eliminated from an 
organism (the half-life of warfarin is 20–60 hours, PCC 
6–8 hours, FFP 1,5 hours- 2 days). Actively bleeding, 
haemodynamically stable patients with therapeutic INR 
value should be given only intravenous Vitamin K, which 
is enough in cases like these. If INR is over a therapeutic 
range, PCC or FFP should be considered. Urgent restor-
ing of coagulation is not necessary for minor bleeding 
that does not cause anaemia. If TNS > 5 low dose of 
Vitamin K can be given orally (1–5 mg) or intravenously 
(1–2.5 mg). [1, 3, 4]
In the described situation, INR value has been in 
the therapeutic range [2, 19]. This INR value does not 
require additional coagulation recovering actions, such 
as Vitamin K, PCC or FFP. Those means have not been 
taken and endoscopy has been arranged immediately. 
Endoscopy has shown a bleeding gastric ulcer, which 
has been clamped and bleeding has been stopped. 
Patients with gastrointestinal bleeding are usually 
treated with proton pump inhibitors (PPIs). When 
gastrointestinal bleeding is suspected, intravenous 
PPIs should be administered empirically (e.g. 80 mg 
esomeprazole bolus i/v, continuing 40 mg twice a day 
intravenously) and continued until the exact location of 
bleeding is detected. [5] The patient has been treated 
with esomeprazole/pantoprazole 80 mg bolus intrave-
nously, continuing 8 mg per hour by automatic syringe 
pump for 3 days. The chosen treatment matches 
recommendations, though it suggests initiating admin-
istration of PPIs as soon as gastrointestinal bleeding 
is suspected. Later on, treatment was continued by 
Sol. Esomeprazole 40 mg twice a day intravenously 
for 2 days and Caps. Omeprazole 20 mg twice a day 
orally afterwards.
After bleeding is stopped endoscopically, a patient 
should be carefully monitored in case of recurrent 
bleeding. If the patient used to take anticoagulating 
agents, it is important to evaluate thrombotic risk and 
decide whether taking those drugs has to be restarted. 
Anticoagulants are usually restarted for patients who 
are haemodynamically stable and the risk for recurrent 
bleeding is low (based on Forrest classification). [6]
The timing of resuming anticoagulating agents de-
pends on the specific drug, that patient has been using 
before. Both ASGE and ESC practical guidelines indi-
cate, that if warfarin has been used, it can be restarted 
at the same evening of the procedure, only if there are 
no signs of recurrent bleeding. To reach therapeutic 
effect might take a few days. [6, 4]
It is recommended to give bridging therapy with 
heparin for patients who have a high risk of thrombo-
sis. The main point of this therapy is the relatively short 
half-life of heparin (1.5 hours), which allows discontin-
uing the usage of preparation immediately if bleeding 
occurs. Bridging therapy should be started patients who 
used to take warfarin in these cases:
1. Embolic stroke or systemic embolic event within the 
previous three months
2. Mechanical mitral valve
3. Mechanical aortic valve and additional stroke risk 
factors
4. Atrial fibrillation and very high risk of stroke (e.g., 
CHADS2  score of 5 or 6, stroke or systemic 
embolism within the previous 12 weeks, concomitant 
rheumatic valvular heart disease with mitral stenosis)
5. Venous thromboembolism within the previous three 
months
6. Recent coronary stenting
7. Previous thromboembolism during interruption of 
chronic anticoagulation [7]
There are 2 kinds of heparin that can be used for 
bridging therapy: low molecular weight heparin (LMWH) 
or unfractionated heparin. 
LMWH is recommended for patients with very high 
(e.g., rheumatic heart disease, permanent atrial fibrilla-
tion with recent embolic stroke, mechanical heart valve) 
or moderate (e.g., active oncological process) arterial 
thromboembolic risk. Unfractionated heparin is a better 
choice in case of renal failure or haemodialysis because 
it is dosing does not depend on renal function. [7]
Heparins can be given in prophylactic, therapeutic 
or intermediate doses. Therapeutic doses are the best 
for patients with a potential source of arterial throm-
boembolism (e.g., atrial fibrillation, mechanical heart 
valve) or venous thromboembolism, which occurred 
within the last month. [7]
Intermediate dosing can be applied for patients with 
atrial fibrillation or venous thromboembolism, which 
occurred within the last month, but there is a greater 
concern of bleeding. [7]
Prophylactic dosing is not applicable for patients 
with atrial fibrillation, because there is no evidence of its 
efficiency in this case. Doses like these can be applied 
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for patients who had venous thromboembolism within 
3–12 month. [7]
Bridging therapy is just a temporary solution, which 
allows reducing thrombotic risk during the acute, 
life-threatening period. Observational studies’ findings 
show that resuming Vitamin K antagonists is the best 
choice after the acute bleeding period is gone, though the 
most appropriate timing to do so is not that well studied. 
3 clinical studies compared the patients, who 
resumed Vitamin K antagonists after gastrointestinal 
bleeding and those who did not. Resuming of Vitamin K 
antagonists has been associated with a significantly lower 
risk of thromboembolic events and death. Furthermore, 
the risk of recurrent bleeding has remained similar. [1]
The ideal timing of resuming anticoagulation drugs 
after gastrointestinal bleeding is poorly studied. Prac-
tical guidelines do not specify when to restart using 
anticoagulants and recommend to do it as soon as 
cardiovascular complications’ risk exceeds the risk of 
bleeding. One of the studies mentioned earlier divided 
653 patients into intervals by the time of resuming 
anticoagulation after bleeding (< 7 days; 15–21 days; 
21–30 days; > 30days). Mortality was lower in those 
cases, when anticoagulation was resumed < 7 days, 
15–21 days and 21–30 days, compared to those, that 
resumed coagulation > 30 days. Patients who start-
ed using warfarin after 7d., had approximately 2 fold 
higher risk of recurrent bleeding and slightly lower risk 
of thromboembolism, compared to those, who did it 
after > 30 days. The incidence of recurrent bleeding 
was similar in all groups that resumed anticoagulation 
after > 7 days, thus it seems that second week after 
gastrointestinal bleeding might be the most reasonable 
timing to restart Vitamin K antagonists. Nevertheless, 
patients in this study were not divided based on a spe-
cific risk for thrombosis and recurrent bleeding. [1]
The patient in the described case, that has perma-
nent atrial fibrillation and mitral valve prosthesis, uses 
warfarin for prevention of thromboembolic events. Ac-
cording to literature sources, 3 factors have to be con-
sidered, while planning to resume anticoagulation- the 
risk of recurrent bleeding, specific anticoagulant, that 
patient used to take before, and thrombotic risk. En-
doscopy has shown a bleeding gastric ulcer with a clot 
underneath, so the risk of recurrent bleeding reaches 
10–20 %. The prosthetic mitral valve is a factor for high 
thrombotic risk, moreover, she has permanent atrial 
fibrillation, which means that there is a need for LMWH 
therapy. [8, 6] The patient has started getting Sol. Na-
droparin 2850 IU twice a day subcutaneously.
On the day of discharge from the hospital, the usage 
of warfarin was still suspended and recommended to 
continue the treatment with Sol. Nadroparin 2850 IU 
twice a day subcutaneously and decide whether to 
restart using warfarin after endoscopy, which was 
planned after almost a month from the day of discharge. 
However, available sources show that it is safe to restart 
warfarin after > 7 days from gastrointestinal bleeding. 
Studies have not shown a significantly higher risk of 
bleeding compared to those cases when warfarin was 
restarted after a month, so it would be reasonable to 
restart it earlier than it has been done. 
All things considered, the treatment for this pa-
tient has been chosen wisely, but based on the latest 
knowledge, more modern viewpoint on restarting 
anticoagulating drugs could be applied. Even though 
gastrointestinal bleeding is a serious life-threatening 
situation, which requires urgent treatment and careful 
monitoring, since active bleeding period had passed, 
more concern should be given to the prevention of 
thromboembolic events.
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